NASDAQ · EYPT
Healthcare · Biotechnology
$0.36
Up+$0.00 (+1.15%)
Updated Nov 8, 2026, 6:35 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EYPT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
EYPT closed at $0.36 after 20 trading sessions, down 89.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $0.3646 | $0.3646 | $0.3305 | $0.36 | 5.98M |
| Nov 5, 2026 | $0.395 | $0.395 | $0.3526 | $0.3559 | 4.22M |
| Nov 4, 2026 | $0.3921 | $0.409 | $0.3801 | $0.395 | 3.07M |
| Nov 3, 2026 | $0.3752 | $0.413 | $0.3752 | $0.3999 | 3.51M |
| Nov 2, 2026 | $0.35 | $0.3799 | $0.349 | $0.3748 | 6.33M |
| Oct 30, 2026 | $0.37 | $0.378 | $0.3446 | $0.3484 | 6.12M |
| Oct 29, 2026 | $0.3815 | $0.42 | $0.3785 | $0.38 | 6.6M |
| Oct 28, 2026 | $0.36 | $0.3944 | $0.36 | $0.3774 | 6.5M |
| Oct 27, 2026 | $0.36 | $0.3918 | $0.3597 | $0.3632 | 9.68M |
| Oct 26, 2026 | $0.40 | $0.4061 | $0.3626 | $0.3657 | 11.13M |
| Oct 23, 2026 | $0.42 | $0.4324 | $0.4016 | $0.4045 | 13.33M |
| Oct 22, 2026 | $0.43 | $0.4388 | $0.42 | $0.4281 | 12.5M |
| Oct 21, 2026 | $0.415 | $0.4382 | $0.386 | $0.43 | 31.69M |
| Oct 20, 2026 | $0.421 | $0.4751 | $0.405 | $0.4052 | 51.03M |
| Oct 19, 2026 | $0.5502 | $0.60 | $0.4025 | $0.44 | 184.37M |
| Oct 16, 2026 | $3.14 | $3.15 | $2.9512 | $2.99 | 2.76M |
| Oct 15, 2026 | $3.02 | $3.175 | $3.009 | $3.14 | 2.84M |
| Oct 14, 2026 | $3.04 | $3.055 | $2.93 | $3.01 | 3.16M |
| Oct 13, 2026 | $3.30 | $3.315 | $3.06 | $3.07 | 2.52M |
| Oct 12, 2026 | $3.42 | $3.4299 | $3.285 | $3.32 | 1.9M |
The latest Smart Investors Daily articles mentioning EYPT.
Company
Market Activity
Research & News
EYPT research
Company profile and research snapshot.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | JP Morgan | Underweight | — |
| Oct 20, 2026 | HC Wainwright & Co. | Neutral | — |
| Oct 20, 2026 | RBC Capital | Sector Perform | — |
| Oct 20, 2026 | Guggenheim | Neutral | — |
| Oct 20, 2026 | Laidlaw & Co. | Hold | — |
No generated briefing is available yet.
Yahoo · Nov 2, 2026
Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeekingAlpha · Oct 29, 2026
EyePoint is downgraded from a speculative Strong Buy to a Hold following LUCIAâs failure, pending greater clarity on cash runway. Read more on EYPT stock here.
Yahoo · Oct 28, 2026
EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChartMill · Oct 21, 2026
Today's unusual-volume list includes PRSO, SHFS, AHT, REED and GUTS, with moves ranging from steep declines to sharp gains on above-average volume.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EYPT.
